Literature DB >> 2881849

Effect of sulphasalazine and its metabolites on the generation of reactive oxygen species.

Y Miyachi, A Yoshioka, S Imamura, Y Niwa.   

Abstract

The relative in vitro anti-oxidant efficacy of sulphasalazine (salicylazosulphapyridine, SASP) and its metabolites (5-aminosalicylic acid, 5-ASA; sulphapyridine, SP) was examined by studying their effects on the generation of reactive oxygen species (ROS) using zymosan-stimulated polymorphonuclear leucocytes (PMNs) and a cell free, xanthine-xanthine oxidase system. Salicylazosulphapyridine, 5-ASA, and SP showed anti-oxidant effects to the various degrees. In particular, production of OH, which is one of the most potent reactive oxygen species, was remarkably suppressed by 5-ASA dose relatedly. These findings suggest that SASP and its metabolites play an important role in the inhibition of respiratory bursts. As the potent products of the respiratory burst by polymorphonuclear leucocytes are thought to be important inflammatory mediators, suppression of toxic reactive oxygen species generation by these agents may partly explain the therapeutic efficacy of SASP in ulcerative colitis, which is characterised by an acute mucosal inflammation dominated by polymorphonuclear leucocytes accumulation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2881849      PMCID: PMC1432978          DOI: 10.1136/gut.28.2.190

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  37 in total

1.  Effects of indomethacin, 5,8,11,14-eicosatetraynoic acid, and p-bromophenacyl bromide on lysosomal enzyme release and superoxide anion generation by human polymorphonuclear leukocytes.

Authors:  J E Smolen; G Weissmann
Journal:  Biochem Pharmacol       Date:  1980-02-15       Impact factor: 5.858

2.  Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease.

Authors:  U Klotz; K Maier; C Fischer; K Heinkel
Journal:  N Engl J Med       Date:  1980-12-25       Impact factor: 91.245

3.  Salicylate other than 5-aminosalicylic acid ineffective in ulcerative colitis.

Authors:  M Campieri; G A Lanfranchi; G Bazzocehi; C Brignola; G Corazza; C Cortini; M Michelini; G Labó
Journal:  Lancet       Date:  1978-11-04       Impact factor: 79.321

4.  Prostaglandin synthetase activity in acute ulcerative colitis: effects of treatment with sulphasalazine, codeine phosphate and prednisolone.

Authors:  P R Smith; D J Dawson; C H Swan
Journal:  Gut       Date:  1979-09       Impact factor: 23.059

5.  Determination of prostaglandin synthetase activity in rectal biopsy material and its significance in colonic disease.

Authors:  D W Harris; P R Smith; C H Swan
Journal:  Gut       Date:  1978-10       Impact factor: 23.059

6.  Sulfasalazine inhibits the synthesis of chemotactic lipids by neutrophils.

Authors:  W F Stenson; E Lobos
Journal:  J Clin Invest       Date:  1982-02       Impact factor: 14.808

7.  Prostaglandin synthesis inhibitors in ulcerative colitis: flurbiprofen compared with conventional treatment.

Authors:  D S Rampton; G E Sladen
Journal:  Prostaglandins       Date:  1981-03

8.  The effect of sulfasalazine and its active components on human polymorphonuclear leukocyte function in relation to ulcerative colitis.

Authors:  L Molin; O Stendahl
Journal:  Acta Med Scand       Date:  1979

9.  Ischemic injury in the cat small intestine: role of superoxide radicals.

Authors:  D A Parks; G B Bulkley; D N Granger; S R Hamilton; J M McCord
Journal:  Gastroenterology       Date:  1982-01       Impact factor: 22.682

10.  Effects of sulphasalazine and its metabolites on prostaglandin synthesis, inactivation and actions on smooth muscle.

Authors:  J R Hoult; P K Moore
Journal:  Br J Pharmacol       Date:  1980-04       Impact factor: 8.739

View more
  43 in total

Review 1.  Sulfasalazine. Multiplicity of action.

Authors:  T S Gaginella; R E Walsh
Journal:  Dig Dis Sci       Date:  1992-06       Impact factor: 3.199

2.  Comparative studies of superoxide production by microbial wall product-primed neutrophils in ulcerative colitis.

Authors:  Sara Elsøe Nielsen; Ben Vainer; Ole Haagen Nielsen
Journal:  Dig Dis Sci       Date:  2004-05       Impact factor: 3.199

3.  Increased DNA strand breaks in mononuclear cells from patients with rheumatoid arthritis.

Authors:  L L Bhusate; K E Herbert; D L Scott; D Perrett
Journal:  Ann Rheum Dis       Date:  1992-01       Impact factor: 19.103

Review 4.  Inflammatory intermediaries in inflammatory bowel disease.

Authors:  K Lauritsen; L S Laursen; K Bukhave; J Rask-Madsen
Journal:  Int J Colorectal Dis       Date:  1989       Impact factor: 2.571

5.  Sulfasalazine reduces bile acid induced apoptosis in human hepatoma cells and perfused rat livers.

Authors:  C Rust; K Bauchmuller; C Bernt; T Vennegeerts; P Fickert; A Fuchsbichler; U Beuers
Journal:  Gut       Date:  2005-12-01       Impact factor: 23.059

Review 6.  Molecular basis of the potential of mesalazine to prevent colorectal cancer.

Authors:  Carmine Stolfi; Roberto Pellegrini; Eleonora Franze; Francesco Pallone; Giovanni Monteleone
Journal:  World J Gastroenterol       Date:  2008-07-28       Impact factor: 5.742

7.  5-aminosalicylic acid (5-ASA) can reduce levels of oxidative DNA damage in cells of colonic mucosa with and without fecal stream.

Authors:  Caroline Caltabiano; Felipe Rodrigues Máximo; Ana Paula Pimentel Spadari; Daniel Duarte da Conceição Miranda; Marcia Milena Pivatto Serra; Marcelo Lima Ribeiro; Carlos Augusto Real Martinez
Journal:  Dig Dis Sci       Date:  2010-11-02       Impact factor: 3.199

Review 8.  Phagocytes, toxic oxygen metabolites and inflammatory bowel disease: implications for treatment.

Authors:  J G Williams
Journal:  Ann R Coll Surg Engl       Date:  1990-07       Impact factor: 1.891

9.  Inhibition of cell mediated cytotoxicity by sulphasalazine: effect of in vivo treatment with 5-aminosalicylic acid and sulphasalazine on in vitro natural killer cell activity.

Authors:  M N Aparicio-Pagés; H W Verspaget; J C Hafkenscheid; G E Crama-Bohbouth; A S Peña; I T Weterman; H W Lamers
Journal:  Gut       Date:  1990-09       Impact factor: 23.059

10.  5-aminosalicylic acid prevents oxidant mediated damage of glyceraldehyde-3-phosphate dehydrogenase in colon epithelial cells.

Authors:  S M McKenzie; W F Doe; G D Buffinton
Journal:  Gut       Date:  1999-02       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.